A groundbreaking clinical initiative, set to commence shortly, focuses on the development of a multimodal cancer pain database. This project intends to leverage the capabilities of artificial intelligence (AI) to advance pain assessment methodologies for oncology-related pain. Backed by Dr. Mark Mulder and the Delft University of Technology, this trial could usher in significant improvements for clinical, quality, and regulatory teams working in oncology and pain management.
Publication date: December 3, 2025
In this article
- What is the focus of the study?
- How will the data be collected?
- Who is leading this initiative?
- Frequently Asked Questions
- Key Implications
- Disclaimer
- Full Announcement Details
What is the focus of the study?
The study primarily focuses on cancer-related pain, a challenging area within oncology due to the diverse ways patients experience and report pain. The database will collect data types such as facial expressions, voice alterations, and responses to questionnaires. These modalities will help develop AI-based tools to objectively assess pain levels, potentially minimizing subjectivity and improving patient outcomes.
How will the data be collected?
Participants will provide audiovisual data and complete questionnaires in two formats: a one-time session and consecutive sessions capturing longitudinal insights. This multimodal methodology aims to provide a robust dataset that accounts for individual variability in pain expression. Such extensive data collection is projected to enhance the AI’s accuracy in identifying and categorizing pain symptoms.
Who is leading this initiative?
Dr. Mark Mulder, with support from the Delft University of Technology, spearheads this development. Their expertise in combining engineering and AI will likely ensure that the database adheres to rigorous scientific and technical standards. Although participant recruitment has not yet begun, the project holds promise for advancing innovation in oncology-focused artificial intelligence.
Frequently Asked Questions
- What is the intended purpose of this database?
The database is designed to support AI-based tools in assessing cancer pain objectively and efficiently. - Who stands to benefit from this study?
Healthcare providers, regulatory and quality teams, and patients experiencing cancer pain will benefit from more standardized pain assessment techniques. - Is the trial recruiting participants?
No, recruitment for this trial has not yet begun.
Key Implications
The development of an AI-supported multimodal database could revolutionize how cancer-related pain is assessed in clinical settings. By reducing subjective errors, improving diagnostic consistency, and tailoring patient care, this initiative addresses key challenges in oncology pain management.
Disclaimer
This content is meant for informational purposes only. It does not constitute legal or medical advice.
Full Announcement Details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07262632?term=medical+device